Taro Pharma Balance Sheet - Annual (NYSE:TARO)

Add to My Stocks
$99.5 $0.45 (0.45%) TARO stock closing price Sep 17, 2018 (Closing)

The fundamental analysis of this company requires a thorough look at Taro Pharma balance sheet. As in our Taro Pharma stock analysis, analyzing a company also involves looking at the company's assets and liabilities as given in its balance sheet, which can be used to measure financial performance. Annual results announcements include the release of all three financial statements, of which the balance sheet is one. Taro Pharma had a long term debt of $- at the end of 2018. To understand the debt servicing capacity of the company, one needs to look at Taro Pharma operating cash flow and Taro Pharma revenue also. Taro Pharma debt to equity ratio is 0.

View latest 10 year balance sheet data to check Taro Pharma financial performance.
show more
View Previous Years
View Next Years
Fiscal year is Apr - Mar2018201720162015201420132012201120102009
Marketable Securities846M786.36M651.86M3.45M3.25M3.18M96.05M3.68M25.96M-
Raw Materials60.7M57.19M51.54M-------
Work In Progress26.85M27.2M26.75M-------
Finished Goods57.03M56.65M60.24M-------
Notes Receivable----------
Other Current Assets-1.01M1.08M-581.63M119.83M98.57M-23.45M14.78M
Total Current Assets
Property Plant & Equipment427.53M398.13M376.57M-------
Accumulated Depreciation233.81M218.04M217.11M-------
Net Property Plant & Equipment
Investment & Advances225.63M70.68M115.17M-----23.76M19.95M
Other Non-Current Assets---46.33M52.89M23.22M19.97M30.97M--
Deferred Charges87.25M---4.9M-----
Deposits & Other Assets29.95M39.95M35.8M4.16M-28.37M32.04M60.21M30.96M31.43M
Total Assets
Notes Payable-------17.31M92.42M90.29M
Accounts Payable25.69M16.39M18.85M19.48M241.33M181.2M187.94M103.53M108.34M66.2M
Current Portion Long-Term Debt----11.97M11.33M10.95M13.59M--
Current Portion Capital Leases----------
Accrued Expenses----------
Income Taxes Payable----------
Other Current Liabilities190.05M193.44M226.6M289.61M----29.37M28.67M
Total Current Liabilities
Deferred Taxes/Income3.22M2.11M2.23M5.38M1.73M5.87M6.61M10.49M11.06M18.65M
Convertible Debt----------
Long-Term Debt---4.97M5.88M17.26M27.94M32.08M--
Non-Current Capital Leases----------
Other Long-Term Liabilities3.82M3.99M3.19M-2.85M---38.7M64.7M
Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus262.44M262.44M262.44M262.44M262.41M-----
Retained Earnings2.66B2.45B1.99B-110.96M969.63M-----
Treasury Stock610M498.67M203.77M194.32M194.32M-----
Other Liabilities-105.04M-141.82M-117.02M1.46B-17.8M-6.61M420.56M--
Shareholders Equity2.21B2.07B1.94B1.42B1.02B890.96M622.95M420.56M247.6M198.59M
Total Liabilities & Shareholders Equity2.43B2.29B2.19B1.74B1.28B1.11B856.42M597.58M527.5M467.12M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Apart from balance sheet items, an investor would do well to keep track of the Taro Pharma stock price by looking at Taro Pharma historical stock prices. One can compare PE with industry average by looking at the Taro Pharma PE ratio chart. The common balance sheet items are:

  • Assets: TARO total assets, which was at $2.43B for 2018 is a balance sheet item representing value of what Taro Pharma owns. Assets are brought to aid a firms operations, or to increase its economic value. It must be noted that tech stocks may not have a lot of assets, as the value for these companies is often derived from future earning potential.
  • Liabilities include short term loans and long term loans availed by the company to fund its business operations. TARO stock had total liabilities of $222.81M for the year 2018.

Taro Pharma Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover
Price to book ratio